MARAS AG, Compliance Officer on behalf of UCB Pharma AG
In the Swiss Medical Weekly, an article written by Prof. Margitta Seek and and Dr Markus Gschwind (University Hospital of Geneva, Switzerland) with the title “Modern management of seizures and epilepsy” has been published .
In table 5 of the published article, where the main features of the drugs are summarised, the prices for a daily dose are also listed. According to the information in the published table, Fycompa® (perampanel) is cheaper than Vimpat® (lacosamide). The price of Vimpat is given as 9.6 CHF/day, based on a dosage of 300 mg/day, and the price of Fycompa as 8.4 CHF/day at the (most frequent) daily dose of 8 mg.
In contrast to the statements made by the authors of the article in the published table, and taking into account the most-used pack and the defined daily dose (DDD; source: WHOCC ATC/DDD index) of these two products, the price of Fycompa® (ex-factory price or public price) per DDD is always greater than that of Vimpat®! You can find the correct numbers in table 1.
|Product||Molecule||Pack size||FAP-PF (CHF)||PP (CHF)||DDD||Dosage||FAP-PF/DDD (CHF)||Variation FAP-PF/DDD*||PP/DDD (CHF)||Variation PP/DDD*|
|Fycompa||Perampanel||8 mg |
|190.33||234.90||8 mg/day||1 tab/day||6.80||12.89%||8.39||11.88%|
|168.6||209.95||300 mg/day||2 tabs/day||6.02||7.50|
May we therefore kindly ask you to correct the statement that Fycompa is less costly than Vimpat? This message is the direct opposite of the true situation and might be a significant commercial drawback for our company.
Dirk Körschenhausen, MD, Director Medical and Regulatory Affairs / CEO, MARAS AG, Alte Steinhauserstrasse 21 , CH-6330 Cham, dirk.koerschenhausen[at]ucb.com
Published under the copyright license
“Attribution – Non-Commercial – NoDerivatives 4.0”.
No commercial reuse without permission.